Serum screening for detection of high-risk group for early-stage diffuse type gastric cancer in Japanese

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 598-602

  Ito, Masanori ^a   Yoshihara, Masaharu ^a   Takata, Shunsuke ^b   Wada, Yoshihiro ^c   Matsuo, Taiji ^a   Boda, Tomoyuki ^a   Tanaka, Shinji ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c Saijo cho   (Japan)

Author keywords

Diffuse type; Gastric cancer; Gastritis; Helicobacter pylori; Pepsinogen

Indexed keywords

BACTERIUM ANTIBODY; PEPSINOGEN I; PEPSINOGEN II;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE TYPE GASTRIC CANCER; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; JAPANESE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STOMACH CANCER;

EID: 84857243043     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06893.x     Document Type: Article

References (25)

1. Matsuda T, Marugame T, Kamo K etal. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 2009; 39: 850-8.
2. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci. Publ. 2004; 157: 327-49.
3. Sakamoto H, Yoshimura K, Saeki N etal. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 2008; 40: 730-40.
4. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48: 3554-60.
5. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J. Gastroenterol. 2010; 45: 1-8.
6. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9: 245-53.
7. Oka S, Tanaka S, Kaneko I etal. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest. Endosc. 2006; 64: 877-83.
8. Yoshihara M, Hiyama T, Yoshida S etal. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand. J. Gastroenterol. 2007; 42: 760-4.
9. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-9.
10. Wada Y, Ito M, Takata S etal. Relationship between Helicobacter pylori tyrosine-phosphorylated CagA-related markers and the development of diffuse-type gastric cancers: a case-control study. Digestion 2010; 82: 10-17.
11. Kikuchi S, Wada O, Miki K etal. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 1994; 73: 2695-702.
12. Yanaoka K, Oka M, Yoshimura N etal. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int. J. Cancer 2008; 123: 917-26.
13. Kiyohira K, Yoshihara M, Ito M etal. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J. Gastroenterol. 2003; 38: 332-8.
14. Miyamoto M, Haruma K, Yoshihara M etal. Five cases of nodular gastritis and gastric cancer: a possible association between nodular gastritis and gastric cancer. Dig. Liver Dis. 2002; 34: 819-20.
15. Kamada T, Miyamoto M, Ito M etal. Nodular gastritis is a risk factor for diffuse-type of gastric carcinoma in Japanese young patients. Gastroenterology 2004; 126: A456.
16. Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol. 2007; 42: 1-15.
17. Fukase K, Kato M, Kikuchi S etal. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 350-2.
18. Ito M, Takata S, Tatsugami M etal. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J. Gastroenterol. 2009; 44: 365-71.
19. Fuccio L, Zagari RM, Eusebi LH etal. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 2009; 151: 121-8.
20. Takenaka R, Okada H, Kato J etal. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment. Pharmacol. Ther. 2007; 25: 805-12.
21. Ogura K, Hirata Y, Yanai A etal. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol. 2008; 42: 279-83.
22. Asaka M, Kato M, Takahashi S etal. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Japanese Society for Helicobacter Research. Helicobacter 2010; 15: 1-20.
23. Yanaoka K, Oka M, Ohata H etal. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int. J. Cancer 2009; 125: 2697-703.
24. Yoshihara M, Sumii K, Haruma K etal. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am. J. Gastroenterol. 1998; 93: 1090-6.
25. Chandanos E, Rubio CA, Lindblad M etal. Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer 2008; 11: 168-74.